Form 4: Adicet Bio Director's Stock Options Reverted to Original Price After Repricing Rescission

Katie Peng, a director at Adicet Bio, had her stock options reverted to their original exercise price following the company's rescission of a prior repricing decision.

Summary

• On August 21, 2024, Adicet Bio's Board of Directors approved the rescission of the August 2023 stock option repricing for certain non-employee directors.
• As a result, Katie Peng's stock options were reverted to their original exercise price.
• The original stock option had an exercise price of $3.38, while the repriced option had an exercise price of $2.14.
• Peng holds options for 70,200 shares of common stock.
• The options vest in 36 equal monthly installments starting July 10, 2023, contingent upon continued service on the Board.

Sentiment

Score: 5

Explanation: The document describes a routine adjustment to stock options, with no inherent positive or negative implications for the company's overall prospects.

Industry Context

Stock option repricing and subsequent rescission are corporate governance actions that can impact director compensation and shareholder value. This action reflects a change in the company's compensation strategy for non-employee directors.

Stakeholder Impact

• The rescission of the stock option repricing may impact the perceived value of director compensation.
• Shareholders may view the change as a reflection of the company's commitment to aligning director incentives with shareholder value.

Key Dates